Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.
Morningstar's Josh Peters on considering yield and growth when looking for dividend-stock opportunities.
Big pharmaceutical companies are getting lean in an attempt to boost profitability before they lose patent protection on several important drugs, says Morningstar's Damien Conover.
Morningstar's Damien Conover discusses the prospects for J&J's stent and drug pipelines.
©2012 Morningstar Advisor. All right reserved.